PepGen Inc. (PEPG) earnings date
Mar 3, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 42 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Nov 10, 2026 | before open | 41 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Tue, May 12, 2026 | after close | 42 | 8-K |
| Q4 FY2025 | Wed, Mar 4, 2026 | after close | 63 | 8-K |
| Q3 FY2025 | Wed, Nov 12, 2025 | before open | 43 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | before open | 38 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | before open | 38 | 8-K |
| Q4 FY2024 | Mon, Feb 24, 2025 | before open | 55 | 8-K |
What they guided beta
| Q3 FY2026 | "PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights – Positive FREEDOM2-DM1 10 mg/kg cohort results demonstrated highest reported splicing correction and improvements across multiple functional measures – – 12.5 mg/kg FREEDOM2-DM1 cohort fully enrolled, with participants having received up to three doses; results expected in 1H 2027 – – FREEDOM-OLE 10 mg/kg safety and 5 mg/kg clinical data expected in January 2027 – – Well-funded with $104.8M of cash as of September 30, 2026, sufficient to fund operations into 2028 –" exhibit |
| Q3 FY2026 | "The 12.5 mg/kg cohort of FREEDOM2 is fully enrolled with all participants having received up to three doses and results are expected in the first half of 2027. o The DSMB also approved dose escalation in the OLE from 5 mg/kg to 10 mg/kg." exhibit |
| Q3 FY2026 | "Interim 10 mg/kg OLE safety and 5 mg/kg OLE clinical data are expected in January 2027. o Building upon the positive results seen at 10 mg/kg, PepGen plans to initiate an expansion cohort, running in parallel to Cohort 3, to generate longer term (up to 9 months) data." exhibit |
| Q3 FY2026 | "PGN-EDODM1 Regulatory Updates: o Data from the FREEDOM2 and FREEDOM-OLE studies ( NCT07220603 ) are expected to support an end-of-Phase 2 (EOP2) meeting in the second half of 2027 pending removal of the partial clinical hold. o In March 2026, PepGen announced that the U.S. Food and Drug Administration (FDA) issued a partial clinical hold on the FREEDOM2 study citing nonclinical findings in mice." exhibit |
| Q3 FY2026 | "Based on currently planned operations, PepGen believes that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operations into 2028." exhibit |
| Q2 FY2026 | "PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights – DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg to 10 mg/kg – – 10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November – – Results from 12.5 mg/kg FREEDOM2-DM1 cohort expected in 1H 2027 – – Well-funded with $117.2M of cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027 –" exhibit |
| Q2 FY2026 | "Read the full release here. o Results from the 12.5 mg/kg cohort of FREEDOM2 are expected in the first half of 2027." exhibit |
| Q2 FY2026 | "Based on currently planned operations, PepGen believes that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operations into the fourth quarter of 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/PEPG
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/PEPG
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/PEPG/"><img src="https://veritasdata.dev/embed/PEPG.svg" alt="PEPG earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/PEPG/)
Script
<script async src="https://veritasdata.dev/embed/PEPG.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/PEPG"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.